Point of present examination work was attempted to figure bilayer tablets of lornoxicam through its joining of oral measurements frame that can release lornoxicam promptly in addition maintained sustained release of lornoxicam for 24 hrs to improve oral bioavailability of lornoxicam. Primary target of this work was plan of bilayer tablets utilizing superdisintegrant Kyron 314 for smart discharge layer Polyox 303 for supporting discharge layer made out of two unique classes of medications by utilizing straight forward simple to-scale-up definition system. The in vitro dissolution study of the prepared bilayer tablets showed a controlled release of active drugs over a period of 24 hours
INTRODUCTION
Oral route is the most commonly employed route of drug administration.
Although different Route of administration are used for the delivery of drugs, oral route remain the preferred mode. The popularity of the oral route is attributed patient acceptance, ease of administration, accurate dosing, cost effective manufacturing method and generally improved shelf-life of the product. Even for sustained release systems the oral route of administration has been investigated the most, because of flexibility in dosage forms design that the oral route offers. With many drugs, the basic goal of therapy is to achieve a steady-state blood level or tissue level that is therapeutically effective and non-toxic for an extended period of time. 1, 2, 3 Bi-layer tablet concept has long been utilized to develop sustained released formulation. Such tablet has a fast releasing layer and may contain one (bi-layer), to sustain the drug release. The pharmacokinetic advantage relies on the criterion that, drug release from the fast releasing layer leads to a sudden rise in the blood concentration. However the blood level is maintained at steady state as the release from sustaining layer. 4, 5, 6 Lornoxicam, a congener of tenoxicam, is a novel NSAID belonging to the oxicam group5 with extremely potent anti-inflammatory and analgesic activities 7, 8 . It is widely used for the symptomatic treatment of pain and inflammation in patients with rheumatoid arthritis and osteoarthritis 9 Bi-layer tablet is sensible for dynamic passage of two medicines in mix, separate two contradicting substances other than for kept up discharge tablet in which one layer is energetic discharge as beginning estimations second layer is reinforce estimation. This bilayer approach is a convenient method. Hence it makes possible to formulate sustained release preparations with the immediate release quantity in one layer and the slow release portion will disintegrate rapidly after ingestion thus providing the Initial dose of medication for immediate onset of action, where as the another layer in
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[133] CODEN (USA): JDDTAO the matrix layer remain intact during most of the time of its passage through the intestine, While dissolving slowly (sustained manner) from its exposed faces in this passage, which helps to maintain the blood level initially reached.
METHODOLOGY
Preformulation study 10 :
Organoleptic Characteristics of Lornoxicam
Physical examine was done to check Organoleptic Characteristics of LORNOXICAM like odor.
Solubility study of Lornoxicam
This study done using different solvents like water, ethanol, methanol, DCM, DMSO.
Preparation of Calibration Curve for Lornoxicam:
100 mg of pure lornoxicam was dissolved in 100 ml of pH 6.8 phosphate buffer. 1 ml of this solution was pipette out in separate 10ml volumetric flask diluted suitable media subjected to UV scanning in range 200-400 nm using double beam UV-visible spectrophotometer.
Preparation of 0.1N HCL:
It was prepared by diluting 8.33 ml of concentrated HCL with 1000 ml with distilled water.
Preparation of Phosphate Buffer 6.8 pH: 2.38 gm of disodium hydrogen phosphate, 0.19gm of potassium dihydrogen phosphate8gm of Nacl were dissolved in water volume up to 1000ml. Adjust pH.
Preparation of Standard solution (100µg/ml): 100mg of lornoxicam was dissolved in ethanol make up 100ml 6.8 phosphate buffer.1ml of solution was pipette out in separate volumetric flask diluted it up to 10 ml with phosphate buffer 6.8 to produce 100µg/ml.
From standard solution of lornoxicam, aliquots of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.70.8 were withdrawn subsequently diluted up to 10 ml with phosphate buffer of pH 6.8 to obtain series of dilutions containing 10, 20, 30, 40, 50, 60, 70, 80 μg/ml solution. Absorbance of these solutions was measured UV-Visible Spectrophotometer at 260 nm using phosphate buffer of pH 6.8 as blank.
Drug-excipients compatibility Studies by FTIR Spectroscopy

11
IR spectroscopy will conducted using FTIR Spectrophotometer spectrum was recorded in wavelength region of400-4000 cm -1 . Procedure consisted of dispersing sample drug alone mixture of drug polymer in KBr compressing into discs by applying pressure of 5 t for 5 min in hydraulic press. Pellet was placed in light path spectrum was recorded.
Preparation of Lornoxicam Bilayer Tablets:
Method of preparation of Sustained Release Layer 12 Lornoxicam sustain release layer had been formulated by utilizing direct compression procedure. Weighed quantities of desired weighed of solid medicament other excipients like MCC, Retardant polymer were mixed properly shifted from sieve no 40. Before compression add talc, magnesium stearate mixed it well. Prepared powder blended than punched by using single punch tablet compression machine. 
Method of Preparation of Immediate release Layer
Lornoxicam Orodispersible layer were prepared by using direct compression method. Desired quantities already weighed material and other excipients like MCC, superdisintegrant, aspartame, agent were mixed properly shifted from sieve no 40. Before compression add talc, magnesium stearate mixed it well. Prepared powder blended than punched by using single punch tablet compression machine.
Drug Content Uniformity
12, 13
Ten Tablets were finely powdered and an amount equivalent to 40 mg of Lornoxicam was accurately weighed and transferred to a 100 ml volumetric flask. Then 70ml methanol was added. The flask was shaken for 10 minutes. Finally, the volume was made up to the mark with methanol. The mixture was then filtered and 1 ml of the filtrate was suitably diluted with methanol to obtain a solution containing about 40 μg ml -1 of Lornoxicam and analyzed for Lornoxicam content at 260 nm using a double beam UV/Visible and methanol as a blank.
In-vitro Drug Release Study of Ketoprofen Bilayer Tablets:
Release of Lornoxicam was determined using a USP, six stage dissolution rate test apparatus-I at 50 rpm. The dissolution was studied using 900 mL of simulated intestinal fluid (without enzyme pH 6.8). The temperature was maintained at 37±0.5 0 C. The sample (5ml) was withdrawn at different time intervals i.e.1,2,3,4,5,6,7,8,9,10,11,12 hrs filter through whatman filter paper and replaced by an equal volume of dissolution medium sample were suitably diluted and analyzed for Lornoxicam content at 376 nm. Table 13 .
Organoleptic Characteristics of Lornoxicam
Preparation of Calibration Curve for Lornoxicam
Absorbance was examined between 200 to 400 nm and λmax was found 376 nm. Table 18 . Alignment bend indicates relapse condition Y= 0.0387xR2value 0.999. Result uncovered that medication focus between 0 -25 µg/mL takes after Beer Lambert's law as relapse coefficient was 0.999. 
Solubility study of Lornoxicam
Identification of Lornoxicam by FT-IR Spectroscopy
Potassium bromide IR circle was readied utilizing 1mg of Lornoxicam on Hydraulic Pellet press checked in locale of 4000-400 cm-1. Gotten IR Spectrum was contrasted reference range of Lornoxicam. O stretching), 3059 (C-H aromatic), 1539 (C=C aromatic), 1327 (C-N) 621 (C-Cl) were observed which confirms identity purity of drug. Trademark tops of medication show up in spectra of blend of medication excipients same wave number, demonstrating no adjustment or communication amongst medication excipients. From that it can infer that medication has kept up its personality without losing its trademark properties. Managed discharge drug conveyance framework required polymers which having property to supported arrival of residue when it is fused into detailing. Retardant polymer, for example, HPMC, Chitosan, Eudragit, Polyox soon are utilized as part of pharmaceutical plan to support medication discharge. Nonetheless, centralization of retardant polymer in managed discharge tablets must be ideal. Here, Polyox 303 has been observed to be extremely powerful retardant polymer for managed discharge tablet delivered by different strategies. Retardant polymer having property of swelling gelling by which they controls arrival of medication from detailing. Actually, viability of Polyox 303 in managing medication discharge is such that it even controls medication discharge without meddling with medication content. Indeed, even retardant polymer like HPMC eudragit has been used for diminishing medication discharge from tablet. Henceforth, LSB3, LSB4LSB 5 have been chosen as enhanced bunches.
Drug-Excipients Compatibility Studies by FT-IR
Preliminary Selection of Type of retardant Material for Lornoxicam sustained Release layer:
Preliminary Selection of Concentration of Retardant Material: As retardant material is essential prerequisite for plan of managed discharge detailing. To improve support discharge, detailing require high centralization of retardant material. According to preparatory trial groups, as convergence of retardant material increment, supporting arrival of medication increment. In this way, 100 mg of retardant material chose as most extreme focus for detailing of managed discharge layer.
Preliminary Trial Batches for Orodispersible Layer:
Preliminary Selection of Type of Super Disintegrants: Orodispersible medication conveyance framework required super disintegrant which is having property to fast arrival of medication when it is joined intoplan. Super disintegrants, for example, Sodium starch glycolate, cross povidone, cross Carmalose sodium, Kyron 314 are utilized as part of pharmaceutical definition for prompt medication discharge. Be that as it may, grouping of super disintegrants in prompt discharge tablets must be ideal. Here, Kyron 314 has been observed to be extremely powerful super disintegrants for immediate discharge tablet delivered by different techniques. Super disintegrants having property of pore framing higher water absorptivity by which they expand arrival of medication from detailing. Indeed, even super disintegrants like cross povidone, cross Carmalose sodium have been used for upgrade medication discharge from tablet. Consequently, LOB2, LOB3LOB5 have been chosen as advanced groups.
In-vitro disintegration Study
In-vitro disintegration study is important to identify disintegration time. As fast tablet disintegrate, gives faster release. As super disintegrants is main need for preparation of sustained release dosage form. To increase quick release, preparation requires optimum amount of super disintegration. Acoording to primary trial batches, as concentration of super disintegrants enhance, release of drug increase. So, 10 percent of super disintegrants selected as optimum concentration for formulation of Orodispersible layer. 
In vitro disintegration effect is significant to know disintegration time. As fast tablet disintegrate, gives faster release.
Figure 9:
In-vitro disintegration study 
CONCLUSION
